This morning, Indaptus Therapeutics, Inc. (INDP) declared that the US Patent and Trademark Office had published a notice of resolution of claims related to the Company’s platform technology. After that, the Indaptus Therapeutics stock price is composing 64.92% in pre-market and is still rising during the day. Despite that, last Wednesday, the trade was closed at $8.92, and in four days, it moderately plummeted by losing over 21%.
A patent entitled “Methods of Treatment of Infections Using Bacteria” (application № 16/584,644) provides broad protection for the application of the technology platform both individually and in conjunction with standard of care for the treatment and inhibition of hepatitis B virus infection (HBV) and human immunodeficiency virus (HIV). The Indaptus pipeline is based on the hypothesis that highly effective anti-tumor or antiviral immunotherapy will require the safe activation of both innate and adaptive immunity both in tumors or foci of infection and in immune organs, and that this can be achieved using a multi-purpose package of bacterial immune system activators in the form of weakened, killed and intact non-pathogenic bacteria delivered intravenously.
Business and Tech Reporter